GlycoNex Incorporation (TPEX: 4168)
Health Care · Biotechnology · TW
NT$22.80
+1.79% today · -4.2% 1Y
GlycoNex Incorporation (TPEX: 4168) operates in the Biotechnology industry within the Health Care sector. The company is valued at $80.23M and employs 25 people.
Over the last twelve months the share price has lost 4.2%, trading between 20.55 and 30.00.
Tweenvest scores GlycoNex Incorporation across four factors: quality 45/100, value 39/100, growth 100/100. Its strongest factor is growth.
4168 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $80.23M
- Revenue (TTM)
- $698.13K
- P/E
- —
- EPS
- -2.44
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- NT$30.00
- 52-week low
- NT$20.55
- Avg volume (3M)
- —
- Shares outstanding
- 112.52M
- Employees
- 25
- Next earnings
- —
About GlycoNex Incorporation
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
- ISIN
- TW0004168000
- Founded
- 2001
- Listed since
- Jun 20, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Prestige Biologics Co., Ltd.KOSDAQ: A334970 | $81.43M | ₩1,408.00 | -1.81% |
| BIONET Therapeutics Corp.TPEX: 7808 | $81.00M | NT$37.00 | -8.64% |
| Sera Prognostics, Inc.NasdaqGM: SERA | $80.48M | $2.06 | +0.74% |
| Greenland Mines LtdNasdaqCM: GRML | $80.35M | $5.46 | -9.39% |
| BioPorto A/SCPSE: BIOPOR | $79.36M | Dkr1.04 | -2.80% |
| Nordicus Partners CorporationOTCPK: NORD | $79.33M | $4.08 | +1.77% |
| Brii Biosciences LimitedSEHK: 2137 | $79.11M | HK$0.86 | -3.37% |
| Pelthos Therapeutics Inc.NYSEAM: PTHS | $78.48M | $20.29 | -1.02% |
Figures last refreshed Oct 11, 2026.